Bio/Pharmaceutical Analysis Techniques

Laboratory Equipment and Instruments

Analytics

Deals, Development and Manufacturing

Inhalation Drugs

Parenterals and Injectables

Solid/Semi-Solid Dosage

Specialty Dosage Drugs

Dosage Forms

APIs and Excipients

Formulation and Drug Delivery

Ingredients

Intellectual Property and Patents

Process and Scaling

Drug Development

Global Perspectives

Intellectual Property & Patents

Aseptic/Sterile Processing

Data and Artificial Intelligence

Equipment

Manufacturing, Biologic Drugs

Manufacturing, Biosimilars and Biobetters

Manufacturing, Cell Therapies

Manufacturing, Gene Therapies

Manufacturing, Inhalation Drugs

Manufacturing, Parenterals and Injectables

Manufacturing, Solid and Semi-Solid Dosage Drugs

Packaging and Distribution

Process and Automation

Supply Chain

Manufacturing

Mergers and Acquisitions

Contract Analytical Services

Contract Development Services

Contract Manufacturing, General

Contract Research Services

Logistics and Distribution

Regulatory Consulting

Outsourcing

Quality Assurance/Quality Control

Regulatory Oversight

Regulatory Oversight and Compliance

Quality Systems

News

Business

Bio/Pharma Business

All News

Top News

Industry News

Bio/Pharma News

Supplier News

News from Europe

Publications

All Publications

PharmTech

PharmTech Europe

Resources

Marketplace

Front & Center

ICH Q9 Revision: A Comprehensive Resource on Quality Risk Management

Peer-Reviewed Research

PharmTech Products

Pharma Insights

Whitepapers

Webcasts

Multimedia

All Videos

Ask the Expert

Behind The Headlines

Buy, Sell, Hold

Drug Digest Videos

Drug Solutions Podcast

Peer Exchange

Sexy Science

Tech Talk

Conference

Conference Coverage

Conference Listing

Events

Subscribe

Pharmaceutical Technology is the independent source for information, insight, and analysis on bio/pharmaceutical formulation, development, and manufacturing.

About Us

Advertise

Contact Us

Editorial Info

Editorial Advisory Board

Do Not Sell My Personal Information

Privacy Policy

Terms and Conditions

Pharmaceutical Technology

Twitter

LinkedIn

Spotlight

Topic

COVID-19 Update

APIs

Analytical Method Development

Aseptic Processing

Biologic Drugs

Drug Delivery

Excipients

Formulation

Packaging

Process Control/PAT

Process Development

QA/QC

Regulatory Action

1rem

The move towards “pharma 4.0” requires a major shift, both ideologically and technologically, to adapt current processes to a framework that will automate much of today’s manufacturing.

Pharma 4.0: What are Industry Leaders Prioritizing in the Modernization of Pharmaceutical Manufacturing? 

The companies will work to create climate-friendly pMDIs using Orbia’s low global warming potential propellant.

Bespak and Orbia Fluor & Energy Materials Collaborate on Climate-Friendly Inhalers

A novel approach for safety assessments in inhalation drugs may avoid animal testing for drug products.

Breathing Easier

Stevanato Group will support development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers.

Stevanato Group and Recipharm to Collaborate on Pre-fillable Syringes for Soft Mist Inhaler

Lonza has joined IPAC-RS, providing benefits to Lonza’s inhalation- related businesses due to IPAC-RS’ global voice of the orally inhaled and nasal drug products industry.

Lonza Joins IPAC-RS, an International Consortium Advancing the Regulatory Science of Inhalation Products

Sustainability in Inhalation and Small-Molecule Drugs

Sustainability and green manufacturing are becoming priorities for the pharmaceutical industry due to evolving and changing regulations to protect both the environment and patients. 

spoke with Andy Burns, vice president, MDI Business Development at Kindeva, about how these developing and complex requirements are impacting contract development and manufacturing organizations. Speaking specifically about the respiratory drug business that he works in, Burns feels there is a revolution happening because of the evolving regulatory changes pertaining to sustainability in the pharma industry.

“We are developing products on behalf of clients where they are looking for more environmentally friendly options, not just through choice, but actually because legislation is dictating their transition needs to happen. So, part of our service is to work with clients, work with our equipment, our research and development people who are experts in this field to produce more environmentally friendly options. For example, European legislation is dictating that phasedown of current products. It will start in 2027 and will finish in 2029. So that's a three-year phasedown period, and beyond that, the usage of existing propellants within metered dose inhalers is going to be limited to a fraction of what it is now. So [they will] still be allowed, but at very, very small volumes. So, we're seeing a big switchover for a lot of companies who are looking to lifecycle manage their existing portfolios, their existing franchises, by reformulating products with new propellants,” says Burns.

Click the video above to watch the interview.

Andy Burns, vice president, MDI Business Development at Kindeva.

Videos

Pharmaceutical Technology® spoke with Andy Burns, vice president, MDI Business Development at Kindeva, about how sustainability requirements are impacting contract development and manufacturing organizations, specifically for the development and manufacture of inhalation drugs. 

PharmTech News

Manufacturing, Inhalation Drugs

Latest News